CNP-103: tolerogenic nanoparticles in recent-onset T1D

What this trial is testing

Every immune therapy for type 1 diabetes (T1D) faces the same trade-off. Drugs that quiet the immune attack — teplizumab, anti-thymocyte globulin, the JAK inhibitors — work by turning down immunity in general. That buys time for the remaining beta cells, but it also turns down the parts of the immune system you actually want, which is why these drugs come with real side effects and why nobody wants to take them forever.

The alternative is antigen-specific tolerance: instead of dialling immunity down, show the immune system the exact protein it is wrongly attacking, in a context that says this one is safe, stand down. Get it right and you would switch off the attack on beta cells while leaving the rest of the immune system intact. This is a decades-old idea in T1D and it has an unhappy track record — GAD-alum reached phase 3 and failed for futility, and oral insulin has repeatedly missed its endpoints.

CNP-103 is a new attempt at that idea using a different delivery vehicle. COUR Pharmaceutical describes it as a tolerogenic nanoparticle: a biodegradable particle that carries T1D autoantigen and presents it to the immune system in a way intended to induce tolerance rather than provoke an attack. NCT06783309 is the first time it has been given to humans.¹

Who is being enrolled, and what happens

The trial is enrolling people aged 12 to 35 who were diagnosed with stage 3 T1D within the previous 180 days and who still have a peak stimulated C-peptide above 0.2 nmol/L on a mixed-meal tolerance test — meaning they are still producing a measurable amount of their own insulin.¹ That window matters: therapies of this kind are trying to preserve beta cells, and you can only preserve what has not yet been destroyed.

Participants receive CNP-103 intravenously in ascending dose cohorts — 100 mg, 300 mg, then 600 mg — or placebo, double-blind. Assessments run through day 365.¹ Estimated enrolment is 72 across 35 US sites; recruitment opened on 12 May 2025 and is ongoing.¹

What the endpoints tell you about the ambition

Read the primary endpoints and the honest scope of this trial becomes obvious. They are (1) the frequency of adverse events and serious adverse events through day 365, and (2) immune safety measured as a panel of serum cytokines — IL-1-beta, TNF-alpha, IL-6, MCP-1, MIP-1-alpha, IFN-gamma, IL-4 and IL-10.¹

Both are safety endpoints. Nothing about C-peptide preservation, HbA1c or time-in-range is a primary outcome here. That is exactly right for a first-in-human study, but it means this trial cannot tell you whether CNP-103 works. It is designed to tell you whether it is safe to keep going — and, via the cytokine panel, whether the particle provokes the inflammatory response you are specifically trying to avoid. Any efficacy signal that emerges will be exploratory, in 72 people, and should be treated as hypothesis-generating rather than as evidence.

What we do not know

Two honest limits on what is written above.

The mechanism is the sponsor's account, not registry fact. The ClinicalTrials.gov record names the drug and the doses but does not describe what CNP-103 carries or how it is supposed to work.¹ The tolerogenic-nanoparticle description comes from COUR itself. We have deliberately not named the specific autoantigens the particle is said to encapsulate, because we have not been able to link a primary source for that detail — and on a site that cites everything, an uncited payload list is not something we will publish. Treat the mechanism as the company's stated design intent until COUR publishes it.

Only an early safety cohort has reported. An ADA 2026 abstract describes the first six adults at 100 mg after day-1 and day-8 dosing: no infusion interruptions, no serious adverse events, and no reported event considered study-product related.² The most common events were sinus discomfort, presyncope, decreased neutrophil count, and low vitamin D. This does not answer whether CNP-103 preserves C-peptide, and it is not a complete safety readout for the planned 72-person trial. Primary completion remains estimated for December 2026, with follow-up to June 2027.¹

Why it is on this site

Antigen-specific tolerance is the most direct assault on the immune attack gap, and the one that — if it ever worked — would also be the cleanest answer to the durable function problem, because you would not need lifelong immunosuppression to keep the result. The field's repeated failures do not make the goal wrong; they make the delivery problem look like the hard part. CNP-103 is a bet on a new delivery vehicle for an old and still-unproven idea. Its first six adults provide a narrow tolerability signal, not evidence of immune tolerance or beta-cell preservation; the complete safety and exploratory efficacy data remain the readout to watch.

References

1. ClinicalTrials.gov. CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed Stage 3 Type 1 Diabetes (NCT06783309). Sponsor: COUR Pharmaceutical Development Company, Inc. Registry update posted 6 August 2026; accessed 8 August 2026. https://clinicaltrials.gov/study/NCT06783309 ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

2. Patel SK, et al. CNP-103: A First-in-Human Phase 1b/2a Study of an Antigen-Specific, Immune-Tolerizing Therapy for Recent-Onset Type 1 Diabetes. ADA 86th Scientific Sessions abstract 2419-P (2026). https://doi.org/10.2337/db26-2419-P ↩